From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients

Cerebrovascular Diseases

Volumn 13, Issue SUPPL. 1, 2002, Pages 22-26

  Hacke, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acetylsalicylic acid; Antiplatelet therapy; Atherothrombosis; Clopidogrel; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ANAMNESIS; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY BLOOD VESSEL; DEATH; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; PRIORITY JOURNAL; RECURRENCE RISK; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ASPIRIN; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; HEPARIN; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL THROMBOSIS; ISCHEMIC ATTACK, TRANSIENT; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; RECURRENCE; RISK FACTORS; TICLOPIDINE;

EID: 0036153984     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047786     Document Type: Conference Paper

References (22)

1. Unifying concept of arterial vascular disease
2. The risk of vascular ischaemic events in patients with various clinical manifestations of atherothrombosis: Data from CAPRIE
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
4. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
5. European stroke prevention study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
6. The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischaemic events
7. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus
8. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis
9. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
10. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel compared with aspirin
11. Biochemical and pharmacological properties of clopidogrel: A new ADP receptor antagonist
12. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
13. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
14. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
15. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis
16. Early potent anti-thrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
17. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy
18. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
19. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
20. Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified?
21. Reduction in major adverse cardiac events, including mortality, after stenting using clopidogrel instead of ticlopidine
22. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation